中新健康丨北大医药董事长徐晰人被刑事拘留

Core Viewpoint - The chairman and president of Peking University Pharmaceutical, Xu Xiren, has been criminally detained, impacting the company's leadership and operations [1][2]. Group 1: Leadership Changes - Xu Xiren was detained on October 29, 2023, and is unable to perform his duties, leading to the delegation of his responsibilities to other executives [1]. - Prior to his detention, Xu had authorized Chen Yuezhong to act as chairman and Yu Mengchuan as president due to "personal reasons" [1]. - Xu Xiren became the actual controller of Peking University Pharmaceutical after acquiring a 22.22% stake through a transaction involving the acquisition of Southwest Synthetic [1][2]. Group 2: Business Challenges - Peking University Pharmaceutical has faced significant operational pressures, including the termination of a long-term service contract with Peking University International Hospital, which accounted for 78.15% of the company's drug distribution revenue in 2024 [3]. - The termination of this contract is expected to lead to a revenue decrease of approximately 600 million yuan and a net profit decrease of about 40 million yuan starting from June 2025 [3]. - The company is also required to undergo a "de-Peking University" reform, which includes changing its name and removing all related branding within a specified timeframe [3]. Group 3: Financial Performance - In the first half of 2025, Peking University Pharmaceutical reported a revenue decline of 5.04% to approximately 957 million yuan, while net profit increased by 15.51% to around 100 million yuan [4]. - The company's cash flow from operating activities decreased significantly by 55.19% to about 23.1 million yuan [4]. Group 4: Market Reaction - Following the news of Xu Xiren's detention, Peking University Pharmaceutical's stock price fell to 5.74 yuan per share, marking a nearly 7% decline [5].